engleski

Treatment of relapsed and refractory aggressive non-Hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE

We report the outcomes of 45 patients with relapsed or refractory aggressive NHL treated with a combination of ifosfamide, carboplatinum and etopoisde (ICE) and 28 patients treated with a combination of ifosfamide, methotrexate and etoposide (IMVP) during two 5-year periods. The response rate (RR) to ICE was 47%, 2-year overall survival (OS) 31% and 2-year event-free survival (EFS) 22%. These results were similar to those obtained with IMVP (RR 39%, 2-year OS 23%, 2-year EFS 13% ; p=0, 355 for RR, 0, 275 for OS, 0, 668 for EFS). Higher IPI scores and refractoriness to treatment were negative prognostic factors, immunophenotype (B vs. T) had no influence on prognosis. Changing from IMVP to ICE, does not substantially improve outcomes of patients with relapsed or refractory aggressive NHL. Patients with relapsed/refractory aggressive B-NHL do not have a superior outcome in comparison to those with T-NHL if treated with chemotherapy alone

Lymphoma non-Hodgkin; Lymphoma B-cell; Lymphoma diffuse; Lymphoma large-cell; Lymphoma T-cell; Ifosfamide; Methotrexate; Etoposide; Carboplatinum

nije evidentirano